2 Unstoppable Dividend Stocks to Double Up on Right Now

Blackstone (BX) remains a leading alternative asset manager with over $1.2 trillion AUM, a forward dividend of $4.69 (≈3% yield) and record Q3 2025 management and advisory fees of over $2.0 billion (up 14% YoY), though performance allocations fell to $781.5 million from $1.6 billion a year earlier, driving total Q3 revenue to ~$3.09 billion (down ~16% YoY) and GAAP net income to ~$625 million (down ~20%); distributable earnings, however, rose 48% to $1.9 billion. Pfizer (PFE) offers a near-7% yield with a forward payout of $1.72, is approaching its 349th consecutive quarterly dividend, and is pursuing growth via the $43 billion Seagen acquisition, a heavy oncology pipeline (≈30% of revenue, >40% of R&D) and a cost realignment targeting $7.7 billion in annual savings by 2027, having returned over $7 billion to shareholders in the first nine months of 2025. Both companies face macro headwinds (inflation, high rates, real-estate volatility) but maintain robust capital-return profiles and strategic pipelines that support longer-term income-oriented allocations.

Analysis

Market structure: Blackstone (BX) and Pfizer (PFE) benefit from bifurcation of capital — institutional demand for alternatives and income-seeking retail demand for high-yield pharma. Winners: large alternative managers, private-credit lenders, oncology/GLP-1 developers; losers: rate-sensitive office REITs and bank B/Ss that compete with private credit. Cross-asset: durable alternatives flows compress demand for long-duration sovereigns (modestly higher yields) and lift private-credit spreads; biotech readouts raise equity implied volatility and drive short-dated option premium spikes.

Risk assessment: Key tail risks are a sharp rate shock that forces BX NAV markdowns and a major negative Phase 3 or regulatory decision at PFE that would pressure the 7% yield. Time horizons: watch BX earnings and distributable earnings cadence over next 30–90 days; expect trial/approval catalysts for PFE over 3–12 months; structural outcomes (BX fee recovery, PFE oncology ramp) play out to 3–5 years. Hidden dependency: BX performance allocations are binary on exits — delayed IPO/M&A windows quickly erase near-term earnings despite rising management fees.

Trade implications: Tactical: establish modest long BX exposure for yield/private-market upside (2–3% portfolio) and use covered-call overlays to harvest income; buy PFE as a 1–2% income + optionality position, funding via short biotech beta. Pair trade: long BX vs short office-heavy REIT ETF (e.g., VNQ overweight to office) to neutralize macro rate moves. Options: sell 6-month BX calls 8–12% OTM to enhance yield; buy 12–18 month PFE LEAPS 0–10% ITM ahead of key oncology/obesity readouts.

Contrarian angles: Market under-weights BX’s 48% surge in distributable earnings despite headline performance-allocation volatility — a recovery in exit activity could re-rate fees and drives asymmetric upside. Conversely, PFE may be over-penalized: a sustained dividend cut is low probability given cash returns of >$7B YTD and cost-savings plan; mispricing exists if yield >6.5% persists after one positive late-stage readout. Watch for unintended consequence: faster M&A by PFE (to fill oncology gaps) could compress near-term free cash flow even as long-term growth improves.

Key Decisions for Investors

• Establish a 2–3% long position in BX within 30 days, size to portfolio risk; implement covered-call overlays by selling 6-month calls ~8–12% OTM to boost yield; trim if quarterly distributable earnings fall >20% QoQ or performance allocations remain <50% of prior-year levels.
• Initiate a 1–2% long position in PFE using staggered buys over 90 days; buy 12–18 month LEAPS (ATM to 10% ITM) sized to 0.5–1% notional to capture oncology/obesity catalysts; exit or cut to 0% if FDA/Phase-3 readout for a material asset is negative or dividend guidance is reduced.
• Put on a relative-value pair: long BX (2%) vs short VNQ (1.5%) for 3–6 month horizon to hedge macro/rate moves and harvest private-market upside; close if 10% divergence in performance or if Fed signals clear easing that materially re-rates REITs.
• If volatility spikes pre-catalyst (>30% IV increase on PFE trials), sell near-term put credit spreads on PFE to collect premium (max exposure 0.5% portfolio) and use proceeds to buy longer-dated LEAPS; avoid option strategies if implied volatility > historical realized by >150 bps.